We are live on ! Find out more
VAXX

Vaxxinity, Inc. Class A Common Stock

Delisted

VAXX was delisted on the 8th of May, 2024.

59 hedge funds and large institutions have $10.9M invested in Vaxxinity, Inc. Class A Common Stock in 2023 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 17 increasing their positions, 9 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 4

89% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 9

13% more funds holding

Funds holding: 5259 (+7)

34% less capital invested

Capital invested by funds: $16.4M → $10.9M (-$5.48M)

Holders
59
Holders Change
+7
Holders Change %
+13.46%
% of All Funds
0.86%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
12
Increased
17
Reduced
9
Closed
4
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Adage Capital Partners
1
Adage Capital Partners
Massachusetts
$2.55M
BlackRock
2
BlackRock
New York
$2.31M +$181K +186,965 +7%
Vanguard Group
3
Vanguard Group
Pennsylvania
$2.03M +$13K +13,451 +0.6%
Geode Capital Management
4
Geode Capital Management
Massachusetts
$716K +$11.8K +12,212 +1%
State Street
5
State Street
Massachusetts
$679K -$32.1K -33,200 -4%
Morgan Stanley
6
Morgan Stanley
New York
$392K +$410K +424,561 +1,164%
Bank of America
7
Bank of America
North Carolina
$305K -$136K -141,301 -28%
Northern Trust
8
Northern Trust
Illinois
$284K -$16.7K -17,314 -5%
Creative Planning
9
Creative Planning
Kansas
$242K +$6.22K +6,443 +2%
BCM
10
Bridgeway Capital Management
Texas
$195K +$149K +154,700 +208%
Pathstone Holdings
11
Pathstone Holdings
New Jersey
$131K +$149K +153,846 New
Bank of New York Mellon
12
Bank of New York Mellon
New York
$103K -$828 -857 -0.7%
Charles Schwab
13
Charles Schwab
California
$102K
IC
14
IEQ Capital
California
$70.8K +$80.4K +83,262 New
Citadel Advisors
15
Citadel Advisors
Florida
$67.5K +$76.7K +79,444 New
ML
16
McAdam LLC
Pennsylvania
$66.5K +$9.66K +10,000 +15%
Barclays
17
Barclays
United Kingdom
$49.7K +$49K +50,698 +650%
N
18
Nuveen
North Carolina
$49.3K
UBS Group
19
UBS Group
Switzerland
$36.6K +$32.5K +33,656 +359%
Millennium Management
20
Millennium Management
New York
$36.5K +$41.4K +42,888 New
LNC
21
Lincoln National Corp
Pennsylvania
$34.9K
BZWA
22
Blue Zone Wealth Advisors
California
$34.9K +$9.66K +10,000 +32%
RhumbLine Advisers
23
RhumbLine Advisers
Massachusetts
$33.2K
JP Morgan Chase
24
JP Morgan Chase
New York
$23.7K +$221 +229 +0.8%
TAM
25
Titleist Asset Management
Texas
$23.5K

VAXX Hedge Fund Activity: Q4 2023 in Review

59 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Vaxxinity, Inc. Class A Common Stock (VAXX) for Q4 2023, worth a combined $10.9M — down 34% from $16.4M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new VAXX positions and 4 closed out — a net gain of 8 holders — while 17 added to existing stakes and 9 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $410K. The largest seller was Scoggin Management, exiting entirely with an estimated $206K sold.

  • 59 institutional investors held Vaxxinity, Inc. Class A Common Stock (VAXX) as of Q4 2023, up from 52 in Q3 2023.
  • Funds reported $10.9M of Vaxxinity, Inc. Class A Common Stock stock for Q4 2023, down 34% quarter-over-quarter.
  • 12 funds opened new Vaxxinity, Inc. Class A Common Stock positions in Q4 2023 and 4 closed out, a net change of +8 holders.
  • The largest Vaxxinity, Inc. Class A Common Stock buyer in Q4 2023 was Morgan Stanley, an estimated $410K added.
  • The largest Vaxxinity, Inc. Class A Common Stock seller in Q4 2023 was Scoggin Management, an estimated $206K sold.

Based on aggregated 13F filings for Q4 2023.